Loading...

PerCP/Cyanine5.5 anti-mouse CD45 Antibody

Pricing & Availability
Clone
30-F11 (See other available formats)
Regulatory Status
RUO
Other Names
T200, Ly-5, LCA
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
30-F11_PerCPCyanine55_CD45_Antibody_082418
C57BL/6 mouse splenocytes were stained with CD45 (Clone 30-F11) PerCP/Cyanine5.5 (filled histogram), or rat IgG2b, ? PerCP/Cyanine5.5 isotype control (open histogram).
  • 30-F11_PerCPCyanine55_CD45_Antibody_082418
    C57BL/6 mouse splenocytes were stained with CD45 (Clone 30-F11) PerCP/Cyanine5.5 (filled histogram), or rat IgG2b, ? PerCP/Cyanine5.5 isotype control (open histogram).
Compare all formats See PerCP/Cyanine5.5 spectral data
Cat # Size Price Quantity Check Availability Save
103131 25 µg 70€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
103132 100 µg 177€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD45 is a 180-240 kD glycoprotein also known as the leukocyte common antigen (LCA), T200, or Ly-5. It is a member of the protein tyrosine phosphatase (PTP) family, expressed on all hematopoietic cells except mature erythrocytes and platelets. There are different isoforms of CD45 that arise from variable splicing of exons 4, 5, and 6, which encode A, B, and C determinants, respectively. CD45 plays a key role in TCR and BCR signal transduction. These isoforms are very specific to the activation and maturation state of the cell as well as cell type. The primary ligands for CD45 are galectin-1, CD2, CD3, CD4, TCR, CD22, and Thy-1.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PerCP/Cyanine5.5 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is = 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

* PerCP/Cyanine5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Clone 30-F11 reacts with all isoforms and both CD45.1 and CD45.2 alloantigens of CD45.

Additional reported applications (for relevant formats) include: immunoprecipitation3, complement-dependent cytotoxicity1,5, immunohistochemistry (acetone-fixed frozen sections, zinc-fixed paraffin-embedded sections and formalin-fixed paraffin-embedded sections)4,6, Western blotting7, and spatial biology (IBEX)10,11. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 103163 and 103164).

Additional Product Notes
BioLegend is in the process of converting the name PerCP/Cy5.5 to PerCP/Cyanine5.5. The dye molecule remains the same, so you should expect the same quality and performance from our PerCP/Cyanine5.5 products. Contact Technical Service if you have any questions.
Application References

(PubMed link indicates BioLegend citation)
  1. Podd BS, et al. 2006. J. Immunol. 176:6532. (FC, CMCD) PubMed
  2. Haynes NM, et al. 2007. J. Immunol. 179:5099. (FC)
  3. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IP)
  4. Simon DI, et al. 2000. J. Clin. Invest. 105:293. (IHC)
  5. Seaman WE. 1983. J. Immunol. 130:1713. (CMCD)
  6. Cornet A, et al. 2001. P. Natl. Acad. Sci. USA 98:13306. (IHC)
  7. Tsuboi S and Fukuda M. 1998. J. Biol. Chem. 273:30680. (WB) PubMed
  8. Liu F, et al. 2012. Blood. 119:3295. PubMed
  9. Pelletier AN, et al. 2012. J. Immunol. 188:5561. PubMed
  10. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  11. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Choi JG, et al. 2020. Front Immunol. 11:598556. PubMed
  2. Gogoi H, et al. 2020. Front Immunol. 1.620833333. PubMed
  3. Daemen S, et al. 2021. Cell Reports. 34(2):108626. PubMed
  4. Zaman R, et al. 2021. Immunity. :. PubMed
  5. Ramakrishna C, et al. 2019. Nat Commun. 10:2153. PubMed
  6. Shah D, et al. 2021. Oncoimmunology. 10:1939601. PubMed
  7. Xiang G, et al. 2022. Cell Death Dis. 13:451. PubMed
  8. Pani F, et al. 2021. Endocrinology. 162:. PubMed
  9. Xiong W, et al. 2022. Nat Commun. 13:1700. PubMed
  10. Tan L, et al. 2022. Aging Dis. 13:1562. PubMed
  11. Jung IY, et al. 2022. Sci Transl Med. 14:eabn7336. PubMed
  12. Krausgruber T, et al. 2020. Nature. 583:296. PubMed
  13. Kawano H, et al. 2016. Int Immunol. 28: 489 - 501. PubMed
  14. Liu W, et al. 2020. Mol Ther Oncolytics. 17:350. PubMed
  15. Yang H, et al. 2019. Mol Metab. 23:24. PubMed
  16. Alissafi T, et al. 2018. J Clin Invest. 128:3840. PubMed
  17. Tan L, et al. 2022. Biochem Biophys Rep. 32:101351. PubMed
  18. Padonou F, et al. 2022. EMBO Rep. 23:e53576. PubMed
  19. Golden GJ, et al. 2021. MBio. 12:e0118121. PubMed
  20. Taddeo A, et al. 2022. NPJ Vaccines. 7:82. PubMed
  21. Li Y, et al. 2022. Int J Biol Sci. 18:3697. PubMed
  22. Tatsuguchi T, et al. 2022. Int Immunol. 34:277. PubMed
  23. Li Z, et al. 2021. Immunology. 163:105. PubMed
  24. Browning D, et al. 2017. Gene Ther. 10.1038/gt.2016.88. PubMed
  25. Rodda LB et al. 2018. Immunity. 48(5):1014-1028 . PubMed
  26. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  27. Hsu SPC, et al. 2020. J Neurooncol. 146:417. PubMed
  28. Yang M, et al. 2020. Cell Prolif. 53:e12784. PubMed
  29. Hanhai Z, et al. 2021. Aging (Albany NY). 13:13108. PubMed
  30. Song J, et al. 2021. J Am Heart Assoc. 10:e017329. PubMed
  31. Sasse C, et al. 2022. Pathogens. 11:. PubMed
  32. Coleby R, et al. 2021. Clin Exp Rheumatol. :39. PubMed
  33. Garcia–Agudo LF, et al. 2019. FASEB J. :fj201900337R. PubMed
  34. Zaytseva D, et al. 2018. Physiol Rep. 6:e13812. PubMed
  35. Schmidleithner L et al. 2019. Immunity. 50(5):1232-1248 . PubMed
  36. Biffi G, et al. 2018. Cancer Discov. 2:282. PubMed
  37. Jazowiecka-Rakus J, et al. 2021. Cancers (Basel). 13:. PubMed
  38. Ren J, et al. 2021. Theranostics. 11:304. PubMed
  39. Craver BM, et al. 2020. Blood Adv. 4:312. PubMed
  40. Chen M, et al. 2021. Cancers (Basel). 13:. PubMed
  41. Peng Z, et al. 2021. STAR Protocols. 2(2):100595. PubMed
  42. Jeong D, et al. 2021. eLife. 0.416666666666667. PubMed
  43. Pan H, et al. 2020. Mol Psychiatry. . PubMed
  44. Damal Villivalam S, et al. 2020. Nat Commun. 4313:11. PubMed
  45. Chaurasiya S, et al. 2020. Oncoimmunology. 9:1729300. PubMed
  46. Somerville TD, et al. 2020. eLife. 9:e53381.. PubMed
  47. Zhong J, et al. 2018. Sci Adv. 4:eaas9864. PubMed
  48. Helm M, et al. 2022. Life (Basel). 12:. PubMed
  49. Potluri HK, et al. 2022. J Immunother Cancer. 10:. PubMed
  50. Papafragkos I, et al. 2022. Front Immunol. 13:889075. PubMed
  51. Liang Z, et al. 2021. J Cell Physiol. 236:4725. PubMed
  52. Fernandez Garcia-Agudo L, et al. 2021. Cell Rep. 36:109548. PubMed
  53. Chung H, et al. 2021. Immune Netw. 21:e28. PubMed
  54. Shen H, et al. 2022. Nat Commun. 13:6030. PubMed
  55. Wang C, et al. 2021. Cell Stem Cell. . PubMed
  56. Fachi JL, et al. 2020. J Exp Med. 217:00:00. PubMed
  57. Sakaguchi M, et al. 2022. Nat Commun. 13:6092. PubMed
  58. Chimenti I, et al. 2022. Cell Death Discov. 8:149. PubMed
  59. Liu Y, et al. 2022. Nat Commun. 13:2665. PubMed
  60. Vijay R, et al. 2015. J Exp Med. 212: 1851 - 1868. PubMed
  61. Fleury M, et al. 2015. Development. 142: 3307 - 3320. PubMed
  62. Osborne JK, et al. 2021. Cell Reports. 36(3):109408. PubMed
  63. Wei SC, et al. 2020. Cancer Discov. . PubMed
  64. Vasilijevic J, et al. 2017. PLoS Pathog. 13:e1006650. PubMed
  65. Caronni N, et al. 2018. Cancer Res. 78:1685. PubMed
  66. Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed
  67. Alexander RK, et al. 2020. eLife. 9:e54090.. PubMed
  68. Voisin M, et al. 2021. Commun Biol. 4:420. PubMed
  69. Edwards CJ, et al. 2021. Br J Cancer. . PubMed
  70. Peres-Emidio EC, et al. 2022. Front Cell Infect Microbiol. 12:811474. PubMed
  71. Cong M, et al. 2021. Methods Mol Biol. 2388:59. PubMed
  72. Frii J, et al. 2021. Immunity. 54(5):1002-1021.e10. PubMed
  73. Nicholas DA, et al. 2020. Scientific Reports. 10(1):13063. PubMed
  74. Deng Z, et al. 2017. Oncogene. 36:639. PubMed
  75. Linde N, et al. 2018. Nat Commun. 9:21. PubMed
  76. Wang W, et al. 2022. Aging Cell. 21:e13630. PubMed
  77. Lee J, et al. 2022. Nat Commun. 13:1516. PubMed
  78. Mansouri S, et al. 2021. J Immunol. 206:2233. PubMed
  79. Li Z, et al. 2022. J Exp Clin Cancer Res. 41:74. PubMed
  80. Mencarelli A, et al. 2016. Sci Rep. 6:30802. PubMed
  81. Li N, et al. 2021. eLife. 10:00. PubMed
  82. Zhao J, et al. 2018. Stem Cell Reports. 10:180. PubMed
  83. Wu Y, et al. 2021. Nat Commun. 12:2346. PubMed
  84. Shi R, et al. 2022. Theranostics. 12:875. PubMed
  85. Akazawa S, et al. 2021. Diabetologia. 64:878. PubMed
  86. Formaglio P, et al. 2021. Immunity. 54:2724. PubMed
  87. Grune J, et al. 2022. Nat Cardiovasc Res. 1:649. PubMed
  88. Witkowski MT, et al. 2020. Cancer Cell. 37:867. PubMed
  89. Hu Y, et al. 2021. Bioact Mater. 2905:6. PubMed
  90. Wen Y, et al. 2020. Hypertension. 869:75. PubMed
  91. Hsu CY, et al. 2020. Frontiers in Immunology. 11:574839. PubMed
  92. Bayik D, et al. 2020. Cancer Discov. 1.256944444. PubMed
  93. Horiguchi H, et al. 2019. Genes Dev. 33:1641. PubMed
  94. Adrover JM et al. 2019. Immunity. 50(2):390-402 . PubMed
  95. Christ A, et al. 2018. Cell. 172:162. PubMed
  96. Hepler C et al. 2018. eLife. 7 pii: e39636. PubMed
  97. Yang J, et al. 2022. Microbiome. 10:149. PubMed
  98. Goldfarb Y, et al. 2021. J Exp Med. 218:. PubMed
  99. Yang Z, et al. 2021. Sci Adv. 7:. PubMed
  100. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
  101. Myerson JW, et al. 2021. Nat Nanotechnol. Online ahead of print. PubMed
  102. Liu Z, et al. 2015. Development. 142: 2452 - 2463. PubMed
  103. Wang Y, et al. 2020. Cell Death Dis. 1.169444444. PubMed
  104. Sharma M, et al. 2020. Circ Res. 127:335. PubMed
  105. Shao M, et al. 2021. Cell Stem Cell. 28(4):685-701.e7. PubMed
  106. Xiang W, et al. 2018. Nat Commun. 9:2574. PubMed
  107. Du Q et al. 2019. Dev Cell. 49(4):618-631 . PubMed
  108. Branchett WJ, et al. 2020. Wellcome Open Research. 0.278472222. PubMed
  109. Shannon JP, et al. 2021. STAR Protoc. 2:100790. PubMed
  110. Krueger A, et al. 2022. Front Microbiol. 12:789042. PubMed
  111. Mittal A, et al. 2021. Sci Rep. 11:10731. PubMed
  112. Germundson DL, et al. 2022. Front Allergy. 3:870513. PubMed
  113. Weinstock A, et al. 2021. Elife. :10. PubMed
  114. Joffin N, et al. 2021. Cell Stem Cell. 28(4):702-717.e8. PubMed
  115. Shannon JP, et al. 2021. Immunity. 54(2):276-290.e5. PubMed
  116. Ballesteros I, et al. 2020. Cell. 183(5):1282-1297.e18. PubMed
  117. Alonso-Herranz L, et al. 2020. Elife. 9:00. PubMed
  118. Sun L, et al. 2015. Sci Rep. 5: 14871. PubMed
  119. Timblin GA, et al. 2021. Nat Metab. 3:618. PubMed
  120. Otvos B, et al. 2021. Clin Cancer Res. 27:2038. PubMed
  121. Lang V, et al. 2021. Elife. 10:. PubMed
  122. Toth K, et al. 2022. PLoS Biol. 20:e3001526. PubMed
  123. Chandra J, et al. 2016. Immunol Cell Biol. 10.1038/icb.2016.83. PubMed
  124. Uematsu T, et al. 2016. Sci Rep. 6:37815. PubMed
  125. Alam Z, et al. 2020. Cell Rep. 107825:31. PubMed
  126. Gubin MM, et al. 2018. Cell. 175:1014. PubMed
  127. Li CJ, et al. 2018. J Clin Invest. 128:5251. PubMed
  128. Tao Z, et al. 2019. Clin Cancer Res. 25:1113. PubMed
  129. Zhang Q, et al. 2021. Front Cell Dev Biol. 9:655552. PubMed
  130. Tuong ZK, et al. 2021. iScience. 24:103326. PubMed
  131. Thomas K, et al. 2022. JCI Insight. :. PubMed
  132. Xu X, et al. 2022. EMBO Rep. 23:e53509. PubMed
  133. Gomez S, et al. 2022. J Immunother Cancer. 10:. PubMed
  134. Shan B, et al. 2020. Nat Metab. 1332:2. PubMed
  135. Mansouri S, et al. 2020. Mucosal Immunol. 0.954861111. PubMed
  136. Martomo SA, et al. 2021. Mol Cancer Ther. 1.074305556. PubMed
  137. Kalafati L, et al. 2020. Cell. 183:771. PubMed
  138. Ngamsri KC, et al. 2020. Front Immunol. 11:407. PubMed
  139. Haider N, et al. 2020. Cell Commun Signal. 18:26. PubMed
  140. Bernstock JD, et al. 2019. J Allergy Clin Immunol. 145:358. PubMed
  141. Dahlgren MW et al. 2019. Immunity. 50(3):707-722 . PubMed
  142. Xu G, et al. 2022. Front Pharmacol. 13:896601. PubMed
  143. Li M, et al. 2021. Cancers (Basel). 13:. PubMed
  144. Dong X, et al. 2022. Front Immunol. 13:896472. PubMed
  145. Pizzurro GA, et al. 2021. Cancers (Basel). 13:. PubMed
  146. Olson B, et al. 2021. Brain Behav Immun. 97:102. PubMed
  147. Calle P, et al. 2021. Cells. 10:. PubMed
  148. Upadhya R, et al. 2016. MBio. 7: 00547-16. PubMed
  149. Yu M, et al. 2021. Molecular Cell. 81(6):1216-1230.e9. PubMed
  150. Zhang H, et al. 2021. Cell Reports. 35(6):109096. PubMed
  151. Ko HJ, et al. 2020. Front Immunol. 1897:11. PubMed
  152. Klose A, et al. 2018. JCSM Rapid Commun. 9:20222. PubMed
  153. Casanova-Acebes M, et al. 2018. J Exp Med. 215:2778. PubMed
  154. Chiang N, et al. 2019. J Clin Invest. 129:5294. PubMed
  155. Scott NA, et al. 2018. Front Immunol. 2.319444444. PubMed
  156. Karolin A, et al. 2022. Front Pharmacol. 12:789080. PubMed
  157. Jazowiecka-Rakus J, et al. 2020. Mol Ther Oncolytics. 18:335. PubMed
  158. Wong NR, et al. 2021. Immunity. 54:2072. PubMed
  159. Mesnieres M, et al. 2021. Cell Reports. 36(8):109618. PubMed
  160. Doss PMIA, et al. 2021. Cell Reports. 34(10):108833. PubMed
  161. Caporarello N, et al. 2020. Aging Cell. 19:e13196. PubMed
  162. Huo M, et al. 2017. FASEB J. 10.1096/fj.201601030R. PubMed
  163. Moufarrij S, et al. 2020. Sci Rep. 10:3470. PubMed
  164. Böhm AM et al. 2019. Dev Cell. 51(2):236-254 . PubMed
  165. Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed
  166. Mello AM, et al. 2022. Oncogenesis. 11:56. PubMed
  167. Shaikh H, et al. 2021. Front Immunol. 12:689896. PubMed
  168. Sánchez-del-Campo L, et al. 2021. J Exp Clin Cancer Res. 40:117. PubMed
  169. Steele NG, et al. 2021. Clin Cancer Res. 27:2023. PubMed
  170. Casselli T, et al. 2021. PLoS Pathog. 17:e1009256. PubMed
  171. Patel K, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.11. PubMed
  172. Tsunekuni K, et al. 2020. J Clin Med. 9:00. PubMed
  173. Yin X, et al. 2020. Cell Rep. 33:108278. PubMed
  174. Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed
  175. Chung S, et al. 2020. Am J Physiol Lung Cell Mol Physiol. L921:318. PubMed
  176. Baron CS, et al. 2018. Nat Commun. 9:2517. PubMed
  177. Gaya M et al. 2018. Cell. 172(3):517-533 . PubMed
  178. Miragaia RJ, et al. 2018. Sci Rep. 8:685. PubMed
  179. Chen L, et al. 2021. Theranostics. 11:6668. PubMed
  180. Sugita Y, et al. 2021. Oncol Rep. 45:. PubMed
  181. Yu H, et al. 2021. Cell Death Dis. 13:1. PubMed
  182. Wang R, et al. 2022. J Immunother Cancer. 10:. PubMed
  183. Zhang Z, et al. 2020. Nature. 579:415. PubMed
  184. Gong P, et al. 2022. Cell Death Discov. 8:466. PubMed
  185. Liu SS, et al. 2021. Immunity. :. PubMed
  186. Wang Y, et al. 2021. Nat Commun. 0.570833333. PubMed
  187. Gao P, et al. 2020. Front Immunol. 1.636111111. PubMed
  188. Sharma M, et al. 2019. Immunometabolism. 1. PubMed
  189. Liang Z, et al. 2017. Autophagy. 14:505. PubMed
  190. Rosen SF, et al. 2022. Genome Med. 14:108. PubMed
  191. Schulze J, et al. 2021. Stroke. 52:2939. PubMed
  192. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  193. Garcia-Alegria E, et al. 2016. Sci Rep. 6: 25917. PubMed
  194. Kim SI, et al. 2020. Molecular Cancer Therapeutics. 20(1):173-182. PubMed
  195. Durga Devi T, et al. 2017. Am J Pathol. 187:2659. PubMed
  196. Wang L, et al. 2020. Nat Commun. 0.654166667. PubMed
  197. Hsu HP, et al. 2021. J Biol Chem. 296:100419. PubMed
  198. Mansouri S, et al. 2021. J Immunol. 206:2233. PubMed
  199. Chen Y, et al. 2021. Braz J Med Biol Res. 54:e9570. PubMed
  200. Caporarello N, et al. 2022. Nat Commun. 13:4170. PubMed
  201. Deptuch T, et al. 2022. Sci Rep. 12:13480. PubMed
  202. Omori S, et al. 2020. Cell Metabolism. 32(5):814-828.e6. PubMed
  203. Xiang W, et al. 2020. Signal Transduct Target Ther. 0.374305556. PubMed
  204. Uematsu T, et al. 2015. Sci Rep. 5: 17577. PubMed
  205. Mitchell LA, et al. 2019. Oncotarget. 10:2252. PubMed
  206. Han Y, et al. 2019. J Clin Invest. 130:26. PubMed
  207. Riopel M, et al. 2019. Mol Metab. 20:89. PubMed
  208. Wirasinha RC, et al. 2021. J Exp Med. 218: . PubMed
  209. Liang Z, et al. 2022. iScience. 25:105233. PubMed
  210. Vogiatzi A, et al. 2021. Mol Cell Biol. 41:e0014921. PubMed
  211. Song X, et al. 2022. Transl Oncol. 15:101306. PubMed
  212. Li X, et al. 2021. Front Immunol. 12:779560. PubMed
  213. Sheriff L, et al. 2020. Dis Model Mech. 13:dmm046383. PubMed
  214. Zheng QY, et al. 2020. FASEB J. 34:10590. PubMed
RRID
AB_893344 (BioLegend Cat. No. 103131)
AB_893340 (BioLegend Cat. No. 103132)

Antigen Details

Structure
Protein tyrosine phosphatase (PTP) family, 180-240 kD
Distribution

All hematopoietic cells except mature erythrocytes and platelets

Function
Phosphatase, T and B cell activation
Ligand/Receptor
Galectin-1, CD2, CD3, CD4, TCR, CD22, Thy-1
Cell Type
B cells, Dendritic cells, Mesenchymal Stem Cells, Tregs
Biology Area
Cell Biology, Immunology, Inhibitory Molecules, Innate Immunity, Neuroscience, Neuroscience Cell Markers, Stem Cells
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Trowbridge IS, et al. 1993. Annu. Rev. Immunol. 12:85.
3. Kishihara K, et al. 1993. Cell 74:143.
4. Pulido R, et al. 1988. J. Immunol. 140:3851.

Gene ID
19264 View all products for this Gene ID
UniProt
View information about CD45 on UniProt.org

Related FAQs

How stable is PerCP/Cyanine5.5 tandem as compared to PerCP alone?

PerCP/Cyanine5.5 is quite photostable and also better than PerCP alone in withstanding fixation.

Other Formats

View All CD45 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD45 30-F11 FC
Biotin anti-mouse CD45 30-F11 FC
FITC anti-mouse CD45 30-F11 FC
PE anti-mouse CD45 30-F11 FC
PE/Cyanine5 anti-mouse CD45 30-F11 FC
Purified anti-mouse CD45 30-F11 FC,IHC-F,CyTOF®,IP,CMCD,IHC,WB
PE/Cyanine7 anti-mouse CD45 30-F11 FC
APC/Cyanine7 anti-mouse CD45 30-F11 FC
Alexa Fluor® 488 anti-mouse CD45 30-F11 FC,SB
Alexa Fluor® 647 anti-mouse CD45 30-F11 FC,ICC,IHC,3D IHC,SB
Pacific Blue™ anti-mouse CD45 30-F11 FC
Alexa Fluor® 700 anti-mouse CD45 30-F11 FC,SB
PerCP/Cyanine5.5 anti-mouse CD45 30-F11 FC
PerCP anti-mouse CD45 30-F11 FC
Alexa Fluor® 594 anti-mouse CD45 30-F11 IHC-F,FC,3D IHC
Brilliant Violet 421™ anti-mouse CD45 30-F11 FC,SB
Brilliant Violet 570™ anti-mouse CD45 30-F11 FC
Brilliant Violet 510™ anti-mouse CD45 30-F11 FC
Brilliant Violet 605™ anti-mouse CD45 30-F11 FC
Purified anti-mouse CD45 (Maxpar® Ready) 30-F11 FC,CyTOF®
PE/Dazzle™ 594 anti-mouse CD45 30-F11 FC
Brilliant Violet 711™ anti-mouse CD45 30-F11 FC
Brilliant Violet 785™ anti-mouse CD45 30-F11 FC
Brilliant Violet 650™ anti-mouse CD45 30-F11 FC
APC/Fire™ 750 anti-mouse CD45 30-F11 FC
Brilliant Violet 750™ anti-mouse CD45 30-F11 FC
TotalSeq™-A0096 anti-mouse CD45 30-F11 PG
TotalSeq™-B0096 anti-mouse CD45 30-F11 PG
Ultra-LEAF™ Purified anti-mouse CD45 30-F11 FC,CyTOF®,IP,CMCD,IHC,WB
Spark Blue™ 550 anti-mouse CD45 30-F11 FC
Spark NIR™ 685 anti-mouse CD45 30-F11 FC
TotalSeq™-C0096 anti-mouse CD45 30-F11 PG
Spark YG™ 570 anti-mouse CD45 30-F11 IHC-F
PE/Fire™ 640 anti-mouse CD45 30-F11 FC
APC/Fire™ 810 anti-mouse CD45 30-F11 FC
PE/Fire™ 700 anti-mouse CD45 30-F11 FC
Spark Violet™ 538 anti-mouse CD45 30-F11 FC
Spark YG™ 593 anti-mouse CD45 30-F11 FC
Spark Blue™ 574 anti-mouse CD45 Antibody 30-F11 FC
Spark UV™ 387 anti-mouse CD45 30-F11 FC
PE/Fire™ 810 anti-mouse CD45 30-F11 FC
Spark Red™ 718 anti-mouse CD45 (Flexi-Fluor™) 30-F11 FC
Spark PLUS UV™ 395 anti-mouse CD45 30-F11 FC
Go To Top Version: 3    Revision Date: 08.24.2018

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account